The neuroprotective effects of caffeine in neurodegenerative diseases.
Identifieur interne : 000024 ( PubMed/Corpus ); précédent : 000023; suivant : 000025The neuroprotective effects of caffeine in neurodegenerative diseases.
Auteurs : Mahshad Kolahdouzan ; Mazen J. HamadehSource :
- CNS neuroscience & therapeutics [ 1755-5949 ] ; 2017.
Abstract
Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.
DOI: 10.1111/cns.12684
PubMed: 28317317
Links to Exploration step
pubmed:28317317Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The neuroprotective effects of caffeine in neurodegenerative diseases.</title>
<author><name sortKey="Kolahdouzan, Mahshad" sort="Kolahdouzan, Mahshad" uniqKey="Kolahdouzan M" first="Mahshad" last="Kolahdouzan">Mahshad Kolahdouzan</name>
<affiliation><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamadeh, Mazen J" sort="Hamadeh, Mazen J" uniqKey="Hamadeh M" first="Mazen J" last="Hamadeh">Mazen J. Hamadeh</name>
<affiliation><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28317317</idno>
<idno type="pmid">28317317</idno>
<idno type="doi">10.1111/cns.12684</idno>
<idno type="wicri:Area/PubMed/Corpus">000024</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000024</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The neuroprotective effects of caffeine in neurodegenerative diseases.</title>
<author><name sortKey="Kolahdouzan, Mahshad" sort="Kolahdouzan, Mahshad" uniqKey="Kolahdouzan M" first="Mahshad" last="Kolahdouzan">Mahshad Kolahdouzan</name>
<affiliation><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Hamadeh, Mazen J" sort="Hamadeh, Mazen J" uniqKey="Hamadeh M" first="Mazen J" last="Hamadeh">Mazen J. Hamadeh</name>
<affiliation><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">CNS neuroscience & therapeutics</title>
<idno type="eISSN">1755-5949</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28317317</PMID>
<DateCreated><Year>2017</Year>
<Month>03</Month>
<Day>20</Day>
</DateCreated>
<DateRevised><Year>2017</Year>
<Month>03</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>23</Volume>
<Issue>4</Issue>
<PubDate><Year>2017</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>CNS neuroscience & therapeutics</Title>
<ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>The neuroprotective effects of caffeine in neurodegenerative diseases.</ArticleTitle>
<Pagination><MedlinePgn>272-290</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.12684</ELocationID>
<Abstract><AbstractText>Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.</AbstractText>
<CopyrightInformation>© 2017 John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kolahdouzan</LastName>
<ForeName>Mahshad</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Muscle Health Research Centre, York University, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hamadeh</LastName>
<ForeName>Mazen J</ForeName>
<Initials>MJ</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-3511-4345</Identifier>
<AffiliationInfo><Affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Muscle Health Research Centre, York University, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>CNS Neurosci Ther</MedlineTA>
<NlmUniqueID>101473265</NlmUniqueID>
<ISSNLinking>1755-5930</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword>
<Keyword MajorTopicYN="N">Huntington disease</Keyword>
<Keyword MajorTopicYN="N">Parkinson disease</Keyword>
<Keyword MajorTopicYN="N">adenosine receptor</Keyword>
<Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword>
<Keyword MajorTopicYN="N">caffeine</Keyword>
<Keyword MajorTopicYN="N">dosage</Keyword>
<Keyword MajorTopicYN="N">neurodegenerative disease</Keyword>
<Keyword MajorTopicYN="N">neuroprotection</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>11</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2017</Year>
<Month>02</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>02</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28317317</ArticleId>
<ArticleId IdType="doi">10.1111/cns.12684</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000024 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000024 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:28317317 |texte= The neuroprotective effects of caffeine in neurodegenerative diseases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28317317" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |